

## Transplantation of low dose CD34<sup>+</sup>Kdr<sup>+</sup> cells promotes vascular and muscular regeneration in ischemic limbs

Paolo Madeddu,<sup>\*,†</sup> Costanza Emanuelli,<sup>\*,‡</sup> Elvira Pelosi,<sup>§</sup> Maria Bonaria Salis,<sup>\*</sup> Anna Maria Cerio,<sup>§</sup> Giuseppina Bonanno,<sup>¶</sup> Mariella Patti,<sup>#</sup> Giorgio Stassi,<sup>#</sup> Gianluigi Condorelli,<sup>\*\*,††</sup> and Cesare Peschle<sup>§,††</sup>

<sup>\*</sup>Experimental Medicine and Gene Therapy, INBB, Osilo and Alghero; <sup>†</sup>Department of Internal Medicine, Sassari University; <sup>‡</sup>Molecular and Cellular Medicine Laboratory, INBB, Alghero and Pula; <sup>§</sup>Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome; <sup>¶</sup>Department of Obstetrics and Gynecology, Catholic University, Rome; <sup>#</sup>Department of Surgical and Oncological Science, University of Palermo; <sup>\*\*</sup>Laboratory of Molecular Cardiology, San Raffaele Biomedical Science Park, Rome, Italy, and <sup>††</sup>Thomas Jefferson University, Philadelphia, PA, USA.

Corresponding authors: Cesare Peschle, M.D., Kimmel Cancer Institute, Thomas Jefferson University, Room 609, 233 South 10th Street, Philadelphia, PA 19107-5541, USA. E-mail: cesare.peschle@mail.jci.tju.edu, and Paolo Madeddu, M.D., Experimental Medicine and Gene Therapy Unit, National Institute of Biostructures and Biosystems (INBB), Via S. Antonio, 07033 Osilo (SS). E-mail: madeddu@yahoo.com

### ABSTRACT

Hematopoietic progenitor cell transplantation can contribute to revascularization of ischemic tissues. Yet, the optimal cell population to be transplanted has yet to be determined. We have compared the therapeutic potential of two subsets of human cord blood CD34<sup>+</sup> progenitors, either expressing the VEGF-A receptor 2 (KDR) or not. In serum-free starvation culture, CD34<sup>+</sup>KDR<sup>+</sup> cells reportedly showed greater resistance to apoptosis and ability to release VEGF-A, as compared with CD34<sup>+</sup>KDR<sup>-</sup> cells. When injected into the hind muscles in immunodeficient SCIDbg mice subjected to unilateral ischemia, a low number (10<sup>3</sup>) of CD34<sup>+</sup>KDR<sup>+</sup> cells improved limb salvage and hemodynamic recovery better than a larger dosage (10<sup>4</sup>) of CD34<sup>+</sup>KDR<sup>-</sup> cells. The neovascularization induced by KDR<sup>+</sup> cells was significantly superior to that promoted by KDR<sup>-</sup> cells. Similarly, endothelial cell apoptosis and interstitial fibrosis were significantly attenuated by KDR<sup>+</sup> cells, which differentiated into mature human endothelial cells and also apparently skeletal muscle cells. This study demonstrates that a low number of CD34<sup>+</sup>KDR<sup>+</sup> cells favors reparative neovascularization and possibly myogenesis in limb ischemia, suggesting the potential use of this cell population in regenerative medicine.

**Key words:** Endothelial progenitor cells • angiogenesis • vasculogenesis • ischemia • apoptosis • vascular endothelial growth factor.

**P**ioneer studies indicated that reparative angiogenesis is bolstered by recruitment of endothelial progenitor cells (EPCs) that functionally incorporate into sites of neovascularization and participate in ongoing collateralization (1). Depletion or functional abnormalities of these cells may contribute to cardiovascular disease progression and impaired

healing after ischemic injury (2–4). Transplantation of EPCs, isolated from adult peripheral blood (APB), cord blood (CB), or bone marrow (BM), has shown great promises as a potential tool to combat ischemic diseases in preclinical animal models (5–9). In addition, preliminary evidence suggests the potential clinical benefit of stem cell therapy for treatment of ischemic diseases in man (10–13). Yet, several important issues must be considered to improve the efficacy and diminish the potential side effects of this approach, including the identification of the optimal cell type for transplantation.

In preclinical and clinical trials, crude preparations of BM or PB mononuclear cells (MNCs) have been generically defined as EPCs, based on their capacity to incorporate acetylated LDL, adhere on fibronectin, and bind ulex-lectin (14). This definition has been questioned, thus leading to the introduction of more specific markers for identification of “bona fide” EPCs [e.g., CD34, AC133, vascular endothelial growth factor A receptor-2 (VEGFR2/Flk-1/KDR) and VE-cadherin] (14–16).

In the embryo, KDR is critical for differentiation of endothelial cells (ECs), vascular smooth muscle cells (VSMCs) and hematopoietic cells (17). In human postnatal life, the small subset of CD34<sup>+</sup>KDR<sup>+</sup> cells are enriched not only for EPCs (15), but also for hematopoietic stem cells (HSCs) and primitive hematopoietic progenitor cells (HPCs) (18), while depleted of more advanced HPCs (18). Furthermore, this subset comprises hemangioblasts endowed with self-renewal capacity and potential for differentiation into both hematopoietic and endothelial cells (19), as well as into other mesodermic tissues (unpublished results). Conversely, CD34<sup>+</sup>KDR<sup>-</sup> cells essentially comprise HPCs.

So far, a side-by-side comparison of the in vivo therapeutic potential of different subpopulations of CD34<sup>+</sup> has been impaired by the low frequency levels of EPC- and HSC-enriched subfractions, e.g., only 1–2% CD34<sup>+</sup> cells stain for KDR. The present study, based on a large supply of CD34<sup>+</sup> cells from human CB, examined whether transplantation of low dose CD34<sup>+</sup>KDR<sup>+</sup> cells into ischemic limbs may improve hemodynamic recovery and tissue healing better than treatment with CD34<sup>+</sup>KDR<sup>-</sup> cells. In addition, we evaluated the contribution of transplanted KDR<sup>+</sup> cells in EC and skeletal myofiber regeneration, as well as in the protection from ischemia-induced apoptosis.

## MATERIALS AND METHODS

### Animals

All procedures complied with the standards stated in the *Guide for the Care and Use of Laboratory Animals* (Institute of Laboratory Animal Resources, National Academy of Sciences, Bethesda, MD). Immunodeficient CB-17/1crHsd-scid-bg mice (Harlan, Italy) were housed at constant room temperature (24±1°C) and humidity (60±3%).

### Cell purification

CB was obtained from healthy, full-term placentas according to institutional guidelines. Low-density mononuclear cells (MNCs) (<1.077 g/ml) were isolated by Ficoll and CD34<sup>+</sup> cells purified by MACS column (Milty, Bergisch Gladbeck, Germany). CD34<sup>+</sup>KDR<sup>+</sup> and CD34<sup>+</sup>KDR<sup>-</sup> subpopulations were sorted by FACS Vantage-SE with specific anti-KDR MoAb

(19). The sorted cells were maintained in Iscove's medium containing 10% FCS at 4°C until used.

### **Induction of ischemia and EPC transplantation**

With mice under the effect of 2,2,2-tribromoethanol anesthesia (880 mmol/kg body wt IP, Sigma, St. Louis, MO), the left femoral artery was exposed, dissected free, and excised (20). On the same occasion, human cord blood cells (CD34<sup>+</sup>KDR<sup>+</sup> [ $10^3$  or  $2 \times 10^3$ ] or CD34<sup>+</sup>KDR<sup>-</sup> [ $10^4$ ], or vehicle (saline) were intramuscularly injected into ischemic limbs. The experimental setting is intended to mimic the clinical situation of patients with extensive, acute arterial occlusion.

### **Postischemic hemodynamic recovery**

Hindlimb blood flow of anesthetized mice was measured by laser Doppler flowmetry (Perimed, Stockholm, Sweden) under basal conditions and then weekly after surgery, and the ratio of perfusion between ischemic to nonischemic foot was calculated (20).

### **Histological assessment of skeletal muscle microcirculation and fibrosis**

At 21 days from ischemia, anesthetized mice were perfusion fixed, and limb muscles were processed for histological analyses. Interstitial fibrosis was morphometrically assessed in Azan Mallory-stained sections and expressed as percent of total muscle section. Vascular ECs were identified by immunostaining for factor VIII (Dako, Carpinteria, CA) or CD31 (JC/70A, CD31 mouse anti-human, Dako) and myofibers by immunostaining for WGA (Fluorescein-labeled Wheat Germ Agglutinin, Vector Laboratories, Burlingame, CA). For identification of arterioles, sections were stained with a mouse monoclonal anti-smooth muscle actin (Sigma). Arterioles were recognized as vascular structures containing one or more continuous layers of smooth muscle cells and morphometrically classified according to their luminal size as small (5 to 25  $\mu$ m in diameter) or large arterioles (25 to 55  $\mu$ m in diameter) (21). Immunostaining for proliferation-associated protein Ki-67 (Ki-67 mouse IgG1, Dako) was performed to identify the rate of EC regeneration.

Histological analysis was performed in a blinded fashion. Capillaries and myofibers were counted with an ocular reticle (9604  $\mu$ m<sup>2</sup> area) at 1000 $\times$  magnification. Twenty-five fields per section were randomly examined and averaged. The number of capillaries ( $n_{cap}$ ) and myofibers ( $n_{fiber}$ ) per field was used to compute capillary or myofiber numerical density per square millimeter of section. Because ischemia can produce myofiber shrinkage, changes in capillarity were also expressed by normalizing capillary density by myofiber density ( $n_{cap}/n_{fiber}$ ). The number of arterioles ( $n_{art}$ ) in the entire section was counted at 1000 $\times$  magnification. Arteriole density per square millimeter of section ( $n_{art}/mm^2$ ) was then calculated.

Apoptosis was assessed by TUNEL assay. TUNEL-positive cell number was counted in the whole area section at 1000 $\times$  magnification and expressed as number of positive cells per square mm section or normalized by capillary or myofiber number.

### **Incorporation of CB-derived progenitor cells into skeletal myofibers**

Immunohistochemical stainings were performed on 5  $\mu$ m thick paraffin sections. Deparaffinized sections were incubated for permeabilization in PBS with 0.1% Triton X-100 for 3 min. After

rinse with PBS, tissue sections were exposed for 2 h at 37°C to mouse monoclonal anti-desmin or anti-dystrophin MoAb (DE-U-10, MANDY S8 respectively, Sigma) or rabbit polyclonal anti-laminin Ab (Sigma) in PBS, 3% bovine serum albumin (BSA) 0.05% Tween 20. After two washes in PBS, sections were incubated for 30 min at 37°C with antibodies against Rhodamine Red (goat anti-mouse IgG (H<sup>+</sup>L) or goat anti-rabbit IgG, Molecular Probes, Carlsbad, CA) in PBS 3% BSA 0.05% Tween 20. Sections were rinsed and incubated with fluorescein-conjugated anti-human nucleus Ag (HNAg) MoAb (MAB 1281, mouse IgG1, Chemicon International, Temecula, CA) diluted 1:50 in PBS 3% BSA 0.05% Tween 20 for 1 h. After two washes nuclei were counterstained using Hoechst 33342 (Molecular Probes). Slides were mounted using fluorescent mounting medium, and then observed and analyzed by confocal laser-scanning microscopy.

### Statistical analysis

All results are expressed as mean  $\pm$  standard error (SEM). Multivariate repeated-measures ANOVA was performed to test for interaction between time and grouping factor. In multiple comparisons in which ANOVA indicated significant differences, the statistical value was determined according to the Bonferroni's method. Differences within and between groups were determined using paired or unpaired Student's *t* test, respectively. The comparative incidence of limb salvage was evaluated by  $\chi^2$  analysis. A *P* value <0.05 was interpreted to denote statistical significance.

## RESULTS

### CD34<sup>+</sup>KDR<sup>+</sup> cell transplantation enhances the neovascularization response to ischemia and protects ECs from apoptosis

In view of the unique resistance of CD34<sup>+</sup>KDR<sup>+</sup> cells to starvation in vitro (22), as well as the marked enrichment of these cells for hematopoietic/endothelial primitive cells (15, 18, 19), we planned to transplant in mouse ischemic limb a low number of CD34<sup>+</sup>KDR<sup>+</sup> cells ( $10^3$  or  $2 \times 10^3$ /mouse) vs. a larger number of CD34<sup>+</sup>KDR<sup>-</sup> ( $10^4$ /mouse). As shown in Fig. 1A, transplantation of  $10^3$  CD34<sup>+</sup>KDR<sup>+</sup> cells increased *capillary density* of ischemic muscles by 114% ( $1408 \pm 96$  vs.  $659 \pm 28$  cap/mm<sup>2</sup> in contralateral normoperfused adductors, *P*<0.01). No further increase in capillarity was observed by doubling the cell dosage. Comparatively, the angiogenic effect promoted by CD34<sup>+</sup>KDR<sup>+</sup> cells largely exceeded (*P*<0.01) the increment seen in muscles injected with vehicle (66%), or  $10^4$  CD34<sup>+</sup>KDR<sup>-</sup> (46%). Capillary to myofiber ratio averaged  $1.25 \pm 0.10$  in ischemic muscles of CD34<sup>+</sup>KDR<sup>+</sup> mice (corresponding to a 64% increment with respect to contralateral adductors, *P*<0.01), a figure significantly higher (*P*<0.05) than that observed in mice given vehicle ( $1.01 \pm 0.08$ , +33% vs. contralateral, *P*<0.05), or CD34<sup>+</sup>KDR<sup>-</sup> subfraction ( $0.94 \pm 0.07$ , +24% vs. contralateral, *P*=N.S.). Thus, transplantation of a low number CD34<sup>+</sup>KDR<sup>+</sup> cells enhanced spontaneous capillarization response to ischemia, while CD34<sup>+</sup>KDR<sup>-</sup> cells were ineffective at 1-log higher number.

Figure 1B shows that arteriogenesis was potentiated by transplantation of CD34<sup>+</sup>KDR<sup>+</sup> cells. Noteworthy, this effect was dosage-dependent; in fact,  $10^3$  CD34<sup>+</sup>KDR<sup>+</sup> cells did not augment the spontaneous increase in arteriole density, while  $2 \times 10^3$  potently stimulated arteriogenesis ( $33.6 \pm 6.5$  art/mm<sup>2</sup>, +352% vs. contralateral, *P*<0.01) as compared with vehicle (142%). In contrast, arteriole density of muscles injected with  $10^4$  CD34<sup>+</sup>KDR<sup>-</sup> cells did not differ from

controls ( $P=N.S.$ ). Morphometric analysis of neovascularization denoted a twofold increment in arteriole diameter in adductor muscles transplanted with  $CD34^+KDR^+$  ( $35\pm7\ \mu m$ ) or  $CD34^+KDR^-$  subfraction ( $29\pm6\ \mu m$ ) as compared with vehicle-injected ( $14\pm5\ \mu m$ ,  $P<0.05$  for both comparisons).

Then, we investigated whether the increase in neovascularization can be attributed to differentiation of the injected primitive cells into mature vascular cells (Fig. 2A, B). Figure 2A illustrates positive controls (human skeletal muscle sections) stained with antibodies against markers of ECs or myofibers (upper panels) and counter-stained with antibodies against human nuclear antigen (HNAg) (lower panels). Figure 3B displays the results of immunohistochemical studies on muscular sections from transplanted mouse adductors. The results of cell counting performed on a total of 2000 capillaries (3 mice/group) revealed  $9.0\pm1.2$  HNAg<sup>+</sup> ECs in capillaries from  $CD34^+KDR^+$  transplanted muscles, as compared with  $2.1\pm0.2$  for the  $CD34^+KDR^-$  group ( $P<0.01$ ). Abundant expression of Ki67, a proliferation-associated protein, was detected in differentiated (HNAg<sup>+</sup>) or nondifferentiated (HNAg<sup>-</sup>) ECs (Fig. 2B). These features were observed at 3 weeks from cell transplantation, suggesting that  $CD34^+KDR^+$  derived ECs continue to proliferate at late stages of reparative process.

Absence of HNAg<sup>+</sup> cells in contralateral (negative controls, right panels of Fig. 2B) or vehicle-injected muscles confirms the specificity of the reaction.

To determine if transplanted CB cells incorporate into the arteriole wall, we screened skeletal muscle sections triple stained with HNAg Ab (green), smooth muscle actin Ab (red) and Hoechst nuclear dye (blue). Figure 2C illustrates immunohistochemical evidence of human nuclei incorporation into arterioles. Incorporation occurred mainly at the level of the endothelial layer (also identified by CD31 immunostaining, not shown), with rare HNAg<sup>+</sup> cells being detectable in arteriole muscular layer (stained in red by smooth muscle actin). The results of cell counting performed in a total of 200 arterioles (3 mice/group) revealed  $1.0\pm0.1$  human nuclear positive cells in vessels from  $CD34^+KDR^+$  transplanted muscles, as compared with  $0.6\pm0.1$  in  $CD34^+KDR^-$  ( $P<0.05$ ). HNAg<sup>+</sup> cells were absent in vessels of muscles injected with vehicle. Similarly, no immunostaining for HNAg was detected in muscles contralateral to those injected with  $CD34^+KDR^+$  or  $CD34^+KDR^-$  (results not shown).

Finally, we evaluated whether CB cell therapy may combat ischemia-induced apoptosis (6 mice/group). TUNEL-positive ECs were significantly less in  $CD34^+KDR^+$  injected adductors ( $3.8\pm0.9$  cells/1000 cap), as compared with vehicle- or  $CD34^+KDR^-$ -injected ones ( $9.5\pm2.5$  and  $8.4\pm1.6$  cells/1000 cap,  $P<0.05$  for both comparisons) (results not shown).

### **$CD34^+KDR^+$ cell transplantation protects skeletal myofiber against apoptosis and causes muscle cell regeneration**

As shown in Fig. 3, apoptosis was dramatically activated by ischemia at myofiber level in the vehicle group ( $69\pm1\%$  of 3500 myofibers examined). This effect was reduced by  $CD34^+KDR^+$  transplantation ( $8\pm1\%$ ,  $P<0.01$ ) and to a significantly lesser extent by  $CD34^+KDR^-$  cells ( $16\pm1\%$ ,  $P<0.01$  vs.  $CD34^+KDR^+$ ). Apoptosis was virtually absent in contralateral normoperfused muscles. Six mice were included in all groups.

We further analyzed the morphology of limb adductor muscles stained with Azan Mallory (4 mice/group). As shown in [Fig. 4](#), interstitial fibrosis was increased in vehicle-injected ischemic muscles ( $54\pm 3\%$  of total section area) as compared with normoperfused contralateral ones ( $3\pm 1\%$ ,  $P<0.01$ ). Transplantation of  $CD34^+KDR^+$  cells resulted in a marked attenuation of fibrosis ( $10\pm 2\%$ ,  $P<0.01$  vs. vehicle), whereas the anti-fibrotic effect of  $CD34^+KDR^-$  cells, transplanted at a 1-log more elevated number, was significantly less pronounced ( $30\pm 1\%$ ,  $P<0.01$  vs.  $CD34^+KDR^+$ ).

To determine the exact location of CB cell incorporation, we performed high-resolution, confocal analysis of skeletal muscle sections stained with antibodies raised against HNAG, dystrophin (a label for sarcolemma), laminin (labeling basal lamina), or desmin (a label for interstitial cells). Donor human nuclei were identified in muscles injected with CB cells underneath the sarcolemma ([Fig. 5A](#)), underneath the basal lamina ([Fig. 5B](#)), as well as in interstitial space ([Fig. 5C](#)) (4 mice/group). The results of cell counting performed in a total of 3500 skeletal myocytes indicate an increased incorporation of  $CD34^+KDR^+$  cells vs.  $CD34^+KDR^-$  cells into the myofibers ( $12.1\pm 0.7$  and  $6.0\pm 0.5$  respectively,  $P<0.01$ ) and underneath the basal lamina ( $8.0\pm 0.9$  and  $4.0\pm 0.7$ ,  $P<0.01$ ), while no group difference was observed with regard to incorporation into cells of the interstitial space ( $15.1\pm 0.5$  and  $12.3\pm 0.6$ ,  $P=N.S.$ ). In contrast, human nuclear positive cells were absent in vehicle-treated ischemic muscles. Similarly, no immunostaining for HNAG was detected in muscles contralateral to those injected with CB cells (results not shown).

### **$CD34^+KDR^+$ cell transplantation improves spontaneous hemodynamic recovery and clinical outcome**

In immunodeficient mice, postischemic healing is severely compromised. Accordingly, 13 (75%) of 18 mice underwent spontaneous foot auto-amputation and the remainders showed an ischemic to contralateral blood flow ratio of  $0.27\pm 0.03$  at 21 days. Clinical outcome remained unaffected by transplantation of  $10^4$   $CD34^+KDR^-$  cells: in fact, 7 (50%) of 14 underwent auto-amputation, with the remainders showing ischemic to contralateral ratio of  $0.28\pm 0.04$  ( $P=N.S.$  vs. vehicle). In contrast,  $2\times 10^3$   $CD34^+KDR^+$  cell transplantation resulted in improved outcome as denoted by reduced auto-amputation rate (15% of 14 mice,  $P<0.05$  vs. vehicle or  $CD34^+KDR^-$  cells). In the remainders, hemodynamic recovery was ameliorated by  $CD34^+KDR^+$  cell transplantation (as denoted by an ischemic to contralateral ratio of  $0.40\pm 0.05$ ,  $P<0.05$  vs. vehicle-treated or  $CD34^+KDR^-$ ). [Figure 6](#) illustrates representative laser Doppler images indicating improved hemodynamic recovery of mice transplanted with  $2\times 10^3$   $CD34^+KDR^+$  cells. A lower dosage ( $10^3$  cells) produced a milder improvement of the clinical outcome (data not shown).

## **DISCUSSION**

In the model of limb ischemia used here, transplantation of  $1-2\times 10^3$  human CB  $CD34^+KDR^+$  cells markedly stimulates spontaneous capillarization. Conversely, transplantation of a larger number ( $10^4$ ) of  $CD34^+KDR^-$  cells is largely ineffective. In the  $CD34^+KDR^+$  cell group, HNAG<sup>+</sup> ECs detected in ischemic muscle at 3 weeks after transplantation showed a high proliferation capacity, as documented by coexpression of Ki-67: this finding newly demonstrates that cells derived from transplanted  $CD34^+KDR^+$  EPCs continuously contribute to reparative angiogenesis up to late stages of the healing process.

Arteriogenesis is likewise potentiated by the proposed cell therapy approach (i.e., arteriole density was significantly increased by  $2 \times 10^3$  CD34<sup>+</sup>KDR<sup>+</sup> cells, whereas  $10^4$  CD34<sup>+</sup>KDR<sup>-</sup> cells were ineffective). Furthermore, the HNAG assay showed that CD34<sup>+</sup>KDR<sup>+</sup> cells incorporate into arterioles with higher frequency than CD34<sup>+</sup>KDR<sup>-</sup> ones. Noteworthy, a cell dose-dependent effect was observed, in that  $10^3$  CD34<sup>+</sup>KDR<sup>+</sup> cells exerted a negligible effect on arterial growth. Therefore, the dosage of  $2 \times 10^3$  CD34<sup>+</sup>KDR<sup>+</sup> seems to be the optimal one for therapeutic purposes.

It should be cautiously noted that the level of incorporation of human EPCs into resident endothelium is too low to account, by itself alone, for the improvement in reparative neovascularization. Additionally, a direct effect of the injected CD34<sup>+</sup>KDR<sup>+</sup> cells on EC proliferation and viability via GF release might be considered. This trophic mechanism is supported by both in vitro and in vivo observations. In vitro studies indicated that CD34<sup>+</sup>KDR<sup>+</sup> cells show a unique capacity to survive in serum-free starvation culture and to release relatively large amounts of VEGF-A, which reportedly exerts a trophic action on endothelial (23) and primitive hematopoietic cells (24). In vivo studies showed that CD34<sup>+</sup>KDR<sup>+</sup> cell transplantation hinders apoptotic cell death and concomitantly reduces fibrosis in ischemic muscles. Recent evidence indicates that ischemia-mobilized EPCs, in the presence of risk factors, may differentiate in harmful cell phenotypes such as macrophages or fibrocytes (25). The possibility that transplanted CD34<sup>+</sup>KDR<sup>+</sup> cells have contributed in fostering vasculogenesis and in preventing endogenous murine EPCs from assuming a proinflammatory, profibrotic phenotype was not assessed in this study, but deserves further investigation.

Furthermore, CB cell transplantation significantly stimulates muscle regeneration. This may derive from the improved reperfusion of the injured limb. Additionally, CB cells might have contributed directly to myogenic regeneration. A recent study documented that murine embryonic and human fetal ECs can differentiate into cardiac myocytes in vitro and in vivo (26). Specifically, EPCs from adult PB may differentiate into functionally active cardiomyocytes when cocultured with rat cardiomyocytes (27). The possibility that cell fusion rather than plasticity mediates these phenomena has been advocated (28). We observed that rare skeletal myocytes were positive for HNAG. Furthermore, expression of human MyoD gene was detected in murine muscles injected with CD34<sup>+</sup>KDR<sup>+</sup> cells, thus suggesting trans-differentiation capacity of these cells into mature myocytes (unpublished results). The presence of HNAG<sup>+</sup> cells outside the fiber basal lamina suggests that CD34<sup>+</sup> cells could differentiate into myogenic cells in the interstitial space before being recruited into the satellite cell pool. Since the frequency of incorporation at the myofiber level was higher for the CD34<sup>+</sup>KDR<sup>+</sup> subset, it is possible that cells derived from this subfraction have a greater capacity to organize within the regenerating muscle. However, the possibility that HNAG<sup>+</sup> positive myocytes could arise from cell fusion rather than from plastic differentiation should be considered.

More important, the present study documents that injection of CD34<sup>+</sup>KDR<sup>+</sup> cells improves the clinical outcome of ischemic muscles and accelerates the rate of hemodynamic recovery. These results indicate that the microvasculature generated with the possible contribution of CD34<sup>+</sup>KDR<sup>+</sup> cells was functionally efficient.

The number of EPCs required for therapeutic vasculogenesis is still unknown. It has been estimated that up to 12 L of autologous blood may be necessary to harvest EPCs in amounts sufficient to induce angiogenesis in patients after intravenous infusion (29). Risk factors,

including atherosclerosis and diabetes, can significantly alter EPC biology and thereby impose additional limitations to autologous transplantation. On the other hand, CB contains a larger number of EPCs than PB, while CB-derived EPCs have distinctive proliferative advantages, including a faster cell-cycle rate and longer telomeres (30). At present, human CB-derived EPC transplantation is negated by rejection triggered by host's immune defense response. In future studies autologous cryopreserved CB-derived EPCs could be used to combat ischemic complications, as already established for CD34<sup>+</sup> cells in the treatment of hematological disorders (31).

The therapeutic efficacy of a small number of CD34<sup>+</sup>KDR<sup>+</sup> cells is a novel and important finding: It compares favorably with previous studies using markedly more elevated number of unselected progenitor cells (6, 29) (also transduced with VEGF in 29). The therapeutic efficacy of low dose CD34<sup>+</sup>KDR<sup>+</sup> cells is seemingly mediated by diverse factors: 1) The CD34<sup>+</sup>KDR<sup>+</sup> subfraction is enriched for EPCs/primitive hematopoietic cells and also comprises hemangioblasts (15, 18, 19); conversely, CD34<sup>+</sup>KDR<sup>-</sup> cells largely comprise HPCs, while they are not enriched for EPCs/primitive hematopoietic cells and do not contain hemangioblasts (15, 19). It is not surprising, therefore, that the CD34<sup>+</sup>KDR<sup>+</sup> cells transplanted in the ischemic area generate human ECs and possibly skeletal muscle cell, whereas the CD34<sup>+</sup>KDR<sup>-</sup> subfraction has a markedly lower cell generation capacity. 2). CD34<sup>+</sup>KDR<sup>+</sup> cells are exquisitely resistant to serum starvation (22); conversely, CD34<sup>+</sup>KDR<sup>-</sup> cells rapidly die in these harsh culture conditions. Similarly, CD34<sup>+</sup>KDR<sup>+</sup> (but not KDR<sup>-</sup>) cells may be resistant to apoptosis when transplanted in the ischemic limb. 3) The release of relatively large amounts of VEGF-A by a small number of CD34<sup>+</sup>KDR<sup>+</sup> cells might exert a significant anti-apoptotic and proliferative action on ECs in the transplanted area (22). Similar mechanisms may underlie the therapeutic effect of low dose CD34<sup>+</sup>KDR<sup>+</sup> cell transplantation in a murine heart infarct model (23).

The CD34<sup>+</sup>KDR<sup>+</sup> transplantation approach also triggers important questions unanswered so far. As previously mentioned, the CD34<sup>+</sup>KDR<sup>+</sup> subset comprises not only EPCs (15), but also primitive hematopoietic cells (18) and hemangioblasts (19). The relative contribution of these functional cell subsets to the diverse ameliorative effects following CD34<sup>+</sup>KDR<sup>+</sup> cell transplantation in the ischemic limb is not clear. It is noteworthy, however, that these functionally different cell populations may represent a single cell pool exhibiting hematopoietic and/or endothelial differentiation in different microenvironmental conditions (19). Also, the number of available CD34<sup>+</sup>KDR<sup>+</sup> cells is limited. In this regard, ongoing studies in our laboratory aim to expand ex vivo the CD34<sup>+</sup>KDR<sup>+</sup> subset, in order to facilitate its therapeutic use at the preclinical and then possibly at the clinical level.

Altogether, we propose that the CD34<sup>+</sup>KDR<sup>+</sup> cell population may be considered as a potentially interesting tool for regenerative therapy in limb ischemia, particularly if coupled with a preliminary ex vivo expansion step inducing primitive cell self-renewal.

#### ACKNOWLEDGMENTS

This work was supported in part by grants from National Institutes of Health (1R01HL63168) to C.P., the Juvenile Diabetes Foundation (No. 2004/124 USA) and Telethon to P.M. We thank M. Blasi and M. Fontana for editorial assistance and A. Zito for graphics.



## REFERENCES


1. Asahara, T., Murohara, T., Sullivan, A., Silver, M., van der Zee, R., Li, T., Witzenbichler, B., Schatteman, G., and Isner, J. M. (1997) Isolation of putative progenitor endothelial cells for angiogenesis. *Science* **275**, 964–967
2. Hill, J. M., Zalos, R. N., Halcox, J. P. J., Schenke, W. H., Waclawiw, M. A., Quyyumi, A. A., and Finkel, T. (2003) Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. *N. Engl. J. Med.* **348**, 593–600
3. Vasa, M., Fichtlscherer, S., Aicher, A., Adler, K., Urbich, C., Martin, H., Zeiher, A. M., and Dimmeler, S. (2001) Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. *Circ. Res.* **89**, E1–E7
4. Tepper, O. M., Galiano, R. D., Capla, J. M., Kalka, C., Gagne, P. J., Jacobowitz, G. R., Levine, J. P., and Gurtner, G. C. (2002) Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. *Circulation* **106**, 2781–2786
5. Orlic, D., Kajstura, J., Chimenti, S., Jakoniuk, I., Anderson, S. M., Li, B., Pickel, J., McKay, R., Nadal-Ginard, B., Bodine, D. M., et al. (2001) Bone marrow cells regenerate infarcted myocardium. *Nature* **410**, 701–705
6. Murohara, T., Ikeda, H., Duan, J., Shintani, S., Sasaki, K., Eguchi, H., Onitsuka, I., Matsui, K., and Imaizumi, T. (2000) Transplanted cord blood-derived endothelial precursor cells augment postnatal neovascularization. *J. Clin. Invest.* **105**, 1527–1536
7. Kawamoto, A., Gwon, H. C., Iwaguro, H., Yamaguchi, J. I., Uchida, S., Masuda, H., Silver, M., Ma, H., Kearney, M., Isner, J. M., et al. (2001) Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia. *Circulation* **103**, 634–637
8. Kalka, C., Masuda, H., Takahashi, T., Kalka-Moll, W. M., Silver, M., Kearney, M., Li, T., Isner, J. M., and Asahara, T. (2000) Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. *Proc. Natl. Acad. Sci. U.S.A.* **97**, 3422–3427
9. Kocher, A. A., Schuster, M. D., Szabolcs, M. J., Takuma, S., Burkhoff, D., Wang, J., Homma, S., Edwards, N. M., and Itescu, S. (2001) Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. *Nat. Med.* **7**, 430–436
10. Tateishi-Yuyama, E., Matsubara, H., Murohara, T., Ikeda, U., Shintani, S., Masaki, H., Amano, K., Kishimoto, Y., Yoshimoto, K., Akashi, H., et al. (2002) Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. *Lancet* **360**, 427–435
11. Assmus, B., Schachinger, V., Teupe, C., Britten, M., Lehmann, R., Dobert, N., Grunwald, F., Aicher, A., Urbich, C., Martin, H., et al. (2002) Transplantation of progenitor cells and regeneration enhancement in myocardial infarction (TOPCARE-AMI). *Circulation* **106**, 3009–3017

12. Strauer, B. E., Brehm, M., Zeus, T., Kosterling, M., Hernandez, A., Sorg, R. V., Kogler, G., and Wernet, P. (2002) Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. *Circulation* **106**, 1913–1918
13. Perin, E. C., Dohmann, H. F., Borojevic, R., Silva, S. A., Sousa, A. L., Mesquita, C. T., Rossi, M. I., Carvalho, A. C., Dutra, H. S., Dohmann, H. J., et al. (2003) Transendocardial, autologous bone marrow cells transplantation for severe, chronic ischemic heart failure. *Circulation* **107**, 2294–2302
14. Rehman, J., Li, J., Orschell, C. M., and March, K. L. (2003) Peripheral blood “endothelial progenitor cells” are derived from monocyte/macrophages and secrete angiogenic growth factors. *Circulation* **107**, 1164–1169
15. Peichev, M., Naiyer, A. J., Pereira, D., Zhu, Z., Lane, W. J., Williams, M., Oz, M. C., Hicklin, D. J., Witte, L., Moore, M. A., et al. (2000) Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. *Blood* **95**, 952–958
16. Gill, M., Dias, S., Hattori, K., Rivera, M. L., Hicklin, D., Witte, L., Girardi, L., Yurt, R., Himel, H., and Rafii, S. (2001) Vascular trauma induces rapid but transient mobilization of VEGFR2(+)AC133(+) endothelial precursor cells. *Circ. Res.* **88**, 167–174
17. Shalaby, F., Ho, J., Stanford, W. L., Fischer, K. D., Schuh, A. C., Schwartz, L., Bernstein, A., and Rossant, J. (1997) A requirement for Flk1 in primitive and definitive hematopoiesis and vasculogenesis. *Cell* **89**, 981–990
18. Ziegler, B., Valtieri, M., Almeida Porada, G., De Maria, R., Muller, R., Masella, B., Gabbianelli, M., Casella, I., Pelosi, E., Bock, T., et al. (1999) KDR receptor: a key marker defining hematolymphopoietic stem cells. *Science* **285**, 1553–1558
19. Pelosi, E., Valtieri, M., Coppola, S., Botta, R., Gabbianelli, M., Lulli, V., Marziali, G., Masella, B., Muller, R., Sgadari, C., et al. (2002) Identification of the hemangioblast in postnatal life. *Blood* **100**, 3203–3208
20. Emanuelli, C., Minasi, A., Zacheo, A., Chao, J., Chao, L., Salis, M. B., Straino, S., Tozzi, M. G., Smith, R., Gaspa, L., et al. (2001) Local delivery of human tissue kallikrein gene accelerates spontaneous angiogenesis in a mouse model of hindlimb ischemia. *Circulation* **103**, 125–132
21. Emanuelli, C., Salis, M.B., Pinna, A., Stacca, T., Milia, A.F., Spano, A., Chao, J., Chao, L., Sciola, L., and Madeddu P (2002) Prevention of diabetes-induced microangiopathy by human tissue kallikrein gene transfer. *Circulation*. **106**, 993–997
22. Botta, R., Gao, E., Stassi, G., Bonci, D., Pelosi, E., Zwas, D., Patti, M., Colonna, L., Baiocchi, M., Coppola, S., et al. (2004 Jul 1 [published online]) Heart infarct in NOD-SCID mice: therapeutic vasculogenesis by transplantation of human CD34<sup>+</sup> cells and low dose CD34<sup>+</sup>KDR<sup>+</sup> cells. *FASEB J.*

23. Gerber, H. P., McMurtrey, A., Kowalski, J., Yan, M., Keyt, B. A., Dixit, V., and Ferrara, N. (1998) Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. *J. Biol. Chem.* **273**, 30,336–30,343
24. Gerber, H. P., Malik, A. K., and Solar, G. P. (2002) VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. *Nature* **417**, 954–958
25. Abe, R., Donnelly, S. C., Peng, T., Bucala, R., and Metz, C. N. (2001) Peripheral blood fibrocytes: differentiation pathway and migration to wound sites. *J. Immunol.* **166**, 7556–7562
26. Condorelli, G., Borello, U., De Angelis, L., Latronico, M., Strabella, D., Coletta, M., Galli, R., Balconi, G., Follenzi, A., Frati, G., et al. (2001) Cardiomyocytes induce endothelial cells to trans-differentiate into cardiac muscle: implications for myocardium regeneration. *Proc. Natl. Acad. Sci. U.S.A.* **98**, 10,733–10,738
27. Badorff, C., Brandes, R. P., Popp, R., Rupp, S., Urbich, C., Aicher, A., Fleming, I., Busse, R., Zeiher, A. M., and Dimmeler, S. (2003) Transdifferentiation of blood-derived human adult endothelial progenitor cells into functionally active cardiomyocytes. *Circulation* **107**, 1024–1032
28. Ying, Q.-L., Nichols, J., Evans, E. P., and Smith, A. G. (2002) Changing potency by spontaneous fusion. *Nature* **416**, 545–548
29. Iwaguro, H., Yamaguchi, J., Kalka, C., Murasawa, S., Masuda, H., Hayashi, S., Silver, M., Li, T., Isner, J. M., and Asahara, T. (2002) Endothelial progenitor cell vascular endothelial growth factor gene transfer for vascular regeneration. *Circulation* **105**, 732–738
30. Murohara, T. (2001) Therapeutic vasculogenesis using human cord blood-derived endothelial progenitors. *Trends Cardiovasc. Med.* **11**, 303–307
31. Grewal, S. S., Kahn, J. P., MacMillan, M. L., Ramsay, N. K., and Wagner, J. E. (2004) Successful hematopoietic stem cell transplantation for Fanconi anemia from an unaffected HLA-genotype-identical sibling selected using preimplantation genetic diagnosis. *Blood* **103**, 1147–1151

*Received April 29, 2004; accepted July 12, 2004.*

**Fig. 1**





**Figure 1. A)** Capillary density in ischemic adductor muscles and contralateral normoperfused ones (open columns). Mice underwent surgical excision of left femoral artery and had ischemic muscles injected with vehicle, cord blood-derived CD34<sup>+</sup>KDR<sup>-</sup> (10<sup>4</sup>) or CD34<sup>+</sup>KDR<sup>+</sup> (10<sup>3</sup> or 2 × 10<sup>3</sup>) cells. Capillary density of ischemic (full columns) and contralateral adductor skeletal muscles (open columns) was counted 21 days after induction of ischemia. Sample number is indicated within columns, and cell dosage is displayed on the abscissa. Values are mean ± SEM. \**P* < 0.05 vs. contralateral; +*P* < 0.05 vs. vehicle and vs. CD34<sup>+</sup>KDR<sup>-</sup>. **B)** Arteriole density in adductor muscles subjected to ischemia (full columns) and contralateral ones (open columns). Values are mean ± SEM. \**P* < 0.05 vs. contralateral; +*P* < 0.05 vs. vehicle and vs. CD34<sup>+</sup>KDR<sup>-</sup>.

Fig. 2



**A**

**HUMAN SKELETAL MUSCLE**

**CONTROL**



**ANTI-NUCLEUS**



**WGA**

**LECTIN**

Fig. 2 (cont)

**B**





Fig. 2 (cont)


**C**

**SMOOTH ACTIN**

**Normal  
Control**





**Ischemic  
Vehicle**



**CD34<sup>+</sup>KDR<sup>+</sup>**




**CD34<sup>+</sup>KDR<sup>-</sup>**



**Figure 2. A, B)** Immunofluorescence analysis of expression of human nuclear antigen (HNAg) (red staining) on cryostat sections of human skeletal muscle counter-stained with antibodies raised against markers of skeletal myofibers (wheat germ agglutinin, WGA) or endothelial cells (lectin, also identified by CD31 immunostaining not shown) (*panel A*, positive control), as compared with mouse left ischemic adductor muscle implanted with CD34<sup>+</sup>KDR<sup>+</sup> (*panel B*, Ad. Left). Contralateral normoperfused nonimplanted muscle is shown as negative control (*panel B*, Ad. Right). HNAg<sup>+</sup> ECs were found to incorporate into vascular tissue of ischemic mouse muscle. Proliferation-associated Ki67 (yellow staining) was detected in HNAg<sup>+</sup> or HNAg<sup>-</sup> ECs. Nuclear counterstaining, performed by Hoechst, is shown in all sections (blue staining). One representative of three independent experiments. **C)** Immunohistochemistry for smooth muscle actin (red) shows the presence of human nuclei stained in green incorporated into arterioles of mouse adductor muscle injected with CD34<sup>+</sup>KDR<sup>+</sup> or CD34<sup>+</sup>KDR<sup>-</sup>. Several HNAg<sup>+</sup> ECs covering the arteriole and venule lumen (also identified by CD31 immunostaining, not shown) are presented (arrowheads). Control normoperfused and vehicle-injected ischemic muscles were negative for human nuclei staining (not shown in figure). Nuclei counterstaining was performed by Hoechst (blue). One representative of 3 independent experiments.




**Fig. 3**



**Figure 3.** DNA breaks were detected by TdT-mediated dUTP nick end labeling (TUNEL) reaction (dark blue) and counterstained with eosin (red color). Black arrowheads indicate apoptotic muscle cells. TUNEL staining shows the absence of apoptosis in muscle fibers in control normoperfused tissue, whereas increased levels of apoptosis are detected in ischemic vehicle tissue as a consequence of ischemia. A significant reduction of apoptotic events is observed in sections of mice injected with  $2 \times 10^3$  CD34<sup>+</sup>KDR<sup>+</sup> cells, while a less pronounced decrease is observed after transplantation of  $10^4$  CD34<sup>+</sup>KDR<sup>-</sup> cells. One representative of 6 independent experiments.

**Fig. 4**





**Figure 4.** Azan Mallory staining shows the normal morphology of muscle fibers in control normoperfused tissue, whereas ischemic vehicle tissue displays relevant increase in fibrosis (blue). Interstitial fibrosis is significantly attenuated in skeletal muscles injected with  $2 \times 10^3$  CD34<sup>+</sup>KDR<sup>+</sup> cells. One representative of 4 independent experiments.

Fig. 5



**A**

**DYSTROPHIN**



**Normal  
Control**



**Ischemic  
Vehicle**



**CD34<sup>+</sup>KDR<sup>+</sup>**



**CD34<sup>+</sup>KDR<sup>-</sup>**






Fig. 5 (cont)


**B**

**LAMININ**


**Normal  
Control**



**Ischemic  
Vehicle**



**CD34<sup>+</sup>KDR<sup>+</sup>**



**CD34<sup>+</sup>KDR<sup>-</sup>**





Fig. 5 (cont)


C

DESMIN


Normal  
Control




Ischemic  
Vehicle



CD34<sup>+</sup>KDR<sup>+</sup>



CD34<sup>+</sup>KDR<sup>-</sup>



**Figure 5.** *A)* Immunofluorescence assay for dystrophin (that labels the sarcolemma, red) performed on paraffin section of mouse adductor muscles. Human HNAg<sup>+</sup> nuclei stained in green (arrowheads) are incorporated into the myofiber underneath the sarcolemma in mice whose ischemic adductor muscles were transplanted with CD34<sup>+</sup>KDR<sup>+</sup> and CD34<sup>+</sup>KDR<sup>-</sup> cells. One representative of four independent experiments. *B)* Immunofluorescence assay for laminin (a basal lamina marker, red) on paraffin section of mouse adductor muscles. HNAg<sup>+</sup> nuclei stained in green (arrowheads) are incorporated underneath the myofiber basal lamina. Nuclei counterstaining was performed by Hoechst (blue). One representative of four independent experiments. *C)* Immunohistochemical analysis of activated satellite cells, revealed by desmin staining, in paraffin section of adductor muscle (red). HNAg<sup>+</sup> nuclei stained in green (arrowheads) indicate human cells differentiated into satellite cells. Nuclei counterstaining was performed by Hoechst (blue). One representative of 4 independent experiments.

Fig. 6

***LASER DOPPLER FLOWMETRY***

**Vehicle**



**75%**

**CD34<sup>+</sup>KDR<sup>-</sup>**



**50%**

**CD34<sup>+</sup>KDR<sup>+</sup>**



**15%**

***AUTO-AMPUTATION***

**Figure 6. Representative laser Doppler images of improved hemodynamic recovery typical of CD34<sup>+</sup>KDR<sup>+</sup> transplanted mice. Abdominal area and ventral parts of limbs and tail are shown. Colors correspond to 6 intervals of perfusion from 0% (dark blue) to 100% (red). Each group consisted of at least 14 mice.**